Calamansi Powder Capsule SupplementationNCT07587905
Effects of Calamansi on Blood Glucose and Insulin Levels
A study testing MMC powder capsule and Calamansi powder capsule in people with Calamansi Powder Capsule Supplementation, run by Burapha University at 1 site in Thailand.
Trial summary
Fifty-four healthy sedentary male and female participants aged 18-30 years will be recruited for this study. Participants will be randomly assigned to one of two groups: a control group receiving placebo MMC capsules (n = 27) or a calamansi capsule supplementation group (n = 27). Read more about this study
- Who is it for?
- Ages 18 to 30 yearsHealthy volunteers can take part
- Conditions the study is for
- Calamansi Powder Capsule Supplementation
- What is being tested?
- MMC powder capsule and Calamansi powder capsule
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 54 participants
- Where
- 1 siteThailand
- Study dates
- 1 May 2026to 31 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy individuals who have not been diagnosed with diabetes or prediabetes, with a fasting blood glucose level (after 8 hours of fasting) of less than 100 mg/dL.
- Aged between 18-30 years, both male and female
- Body Mass Index (BMI) between 18.5 and 22.9 kg/m²
- No diseases affecting blood sugar levels, such as liver or pancreatic diseases
Who cannot join
- Pregnant or breastfeeding women
- Regular smokers
- Regular alcohol consumers
- Individuals with a history of allergies to citrus fruits or citrus-derived ingredients
- Individuals taking medications that affect glucose metabolism and fat distribution in the body, including steroids, protease inhibitors, and psychiatric medications. These refer to drugs that act on the central nervous system and may affect blood sugar levels or energy metabolism, such as antidepressants, antipsychotics, and mood stabilizers.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Thailand1 site, 1 recruiting
- Recruiting
Piyapong Prasertsri
Mueang, Burapha University, 20131
Piyapong Prasertsri, Ph.D., 6638103166, piyapong@buu.ac.th
Kulwara Poolpol, Ph.D., 6638103147, kulwara@go.buu.ac.th
About this study
Official title: The Effects of Calamansi (Citrus x Macrocarpa Bunge) Supplementation on Blood Glucose and Insulin Levels in Healthy Volunteers
Fifty-four healthy sedentary male and female participants aged 18-30 years will be recruited for this study. Participants will be randomly assigned to one of two groups: a control group receiving placebo MMC capsules (n = 27) or a calamansi capsule supplementation group (n = 27). All participants will undergo health screening procedures, including medical history assessment, mental health questionnaire evaluation, and measurements of vital signs, height, body weight, and body composition. Venous blood samples will subsequently be collected to determine blood glucose, insulin, creatinine, alanine aminotransferase (ALT), and malondialdehyde (MDA) levels. These assessments will be performed at three time points: 1) before capsule supplementation (baseline), 2) following a single dose of capsule supplementation, and 3) after 12 weeks of supplementation.
- Conditions
- Calamansi Powder Capsule Supplementation
- Being tested
- MMC powder capsule, Calamansi powder capsule
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MMC powder capsuleOther
Each capsule contains MMC powder for 500 mg
Calamansi powder capsuleDietary supplement
Each capsule contains calamansi powder for 500 mg
| Study group | Role | What they receive |
|---|---|---|
| MMC powder capsule | Placebo comparator | Participants will be randomly assigned to an intervention arm. During the short-term phase, participants in the control group will receive microcrystalline cellulose (MMC) capsules and will be instructed to consume 1,500 mg/day (three capsules). During the long-term phase, participants will continue consuming MMC at a dose of 1,500 mg/day (three capsules), taken within 15-30 min after breakfast. All supplementation will be administered at the participants' residences. Receives: Other: MMC powder capsule |
| Calamansi powder capsule | Experimental | Participants will be randomly assigned to an intervention arm. During the short-term phase, participants in the calamansi group will receive calamansi powder capsules and will be instructed to consume 1,500 mg/day (three capsules). During the long-term phase, participants will continue consuming calamansi powder capsules at a dose of 1,500 mg/day (three capsules), taken within 15-30 min after breakfast. All supplementation will be administered at the participants' residences. Receives: Dietary Supplement: Calamansi powder capsule |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentrations of blood glucose
Concentrations of blood glucose were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in mg/dL unit
Measured: At 0 minute before consumption, at 30, 60, 90, 120 minutes after consumption, and at days 91 after consumption
Concentrations of blood insulin
Concentrations of blood insulin were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uU/mL (microunit/milliliter) unit
Measured: At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption
Concentrations of blood malondialdehyde
Concentrations of blood malondialdehyde were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uM (micromolar) unit
Measured: At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption
Secondary outcomes (1)
Levels of heart rate variability
Heart rate variability were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in ms (milliseconds) and ms2 (millisecond squared) unit
Measured: At 0-10 minutes before consumption, at 110-120 minutes after consumption, and at days 91 after consumption for 10 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start1 May 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Calamansi Powder Capsule SupplementationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly divided into 2 groups consisting of placebo group (n = 27) or a treatment group (n = 27).
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 54 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Burapha University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Piyapong Prasertsri, Burapha University
- Investigators
- Piyapong Prasertsri, Ph.D., Principal investigator, Faculty of Allied Health Sciences, Burapha University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07587905
- Sponsor's protocol ID
- IRB1-033/2569
- Status last verified
- May 2026
- First submitted
- 8 May 2026
- Last updated
- 15 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: There is no plan to make individual participant data available to other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Calamansi (Citrus x Macrocarpa Bunge) Supplementation on Blood Glucose and Insulin Levels in Healthy Volunteers
- ClinicalTrials.gov ID
- NCT07587905
- Acronym / sponsor ID
- IRB1-033/2569
- Conditions
- Calamansi Powder Capsule Supplementation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 54 participants (estimated)
- Lead sponsor
- Burapha UniversityUniversity, hospital or other
- Study start
- 1 May 2026 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Jan 2027 (estimated)
- First posted
- 14 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fifty-four healthy sedentary male and female participants aged 18-30 years will be recruited for this study. Participants will be randomly assigned to one of two groups: a control group receiving placebo MMC capsules (n = 27) or a calamansi capsule supplementation group (n = 27). All participants will undergo health screening procedures, including medical history assessment, mental health questionnaire evaluation, and measurements of vital signs, height, body weight, and body composition. Venous blood samples will subsequently be collected to determine blood glucose, insulin, creatinine, alanine aminotransferase (ALT), and malondialdehyde (MDA) levels. These assessments will be performed at three time points: 1) before capsule supplementation (baseline), 2) following a single dose of capsule supplementation, and 3) after 12 weeks of supplementation.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Participants will be randomly divided into 2 groups consisting of placebo group (n = 27) or a treatment group (n = 27).
| Arm | Type | Receives |
|---|---|---|
| MMC powder capsule | Placebo comparator | Other: MMC powder capsuleParticipants will be randomly assigned to an intervention arm. During the short-term phase, participants in the control group will receive microcrystalline cellulose (MMC) capsules and will be instructed to consume 1,500 mg/day (three capsules). During the long-term phase, participants will continue consuming MMC at a dose of 1,500 mg/day (three capsules), taken within 15-30 min after breakfast. All supplementation will be administered at the participants' residences. |
| Calamansi powder capsule | Experimental | Dietary Supplement: Calamansi powder capsuleParticipants will be randomly assigned to an intervention arm. During the short-term phase, participants in the calamansi group will receive calamansi powder capsules and will be instructed to consume 1,500 mg/day (three capsules). During the long-term phase, participants will continue consuming calamansi powder capsules at a dose of 1,500 mg/day (three capsules), taken within 15-30 min after breakfast. All supplementation will be administered at the participants' residences. |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy individuals who have not been diagnosed with diabetes or prediabetes, with a fasting blood glucose level (after 8 hours of fasting) of less than 100 mg/dL.
- Aged between 18-30 years, both male and female
- Body Mass Index (BMI) between 18.5 and 22.9 kg/m²
- No diseases affecting blood sugar levels, such as liver or pancreatic diseases
Key exclusion criteria (5 listed)
- Pregnant or breastfeeding women
- Regular smokers
- Regular alcohol consumers
- Individuals with a history of allergies to citrus fruits or citrus-derived ingredients
- Individuals taking medications that affect glucose metabolism and fat distribution in the body, including steroids, protease inhibitors, and psychiatric medications. These refer to drugs that act on the central nervous system and may affect blood sugar levels or energy metabolism, such as antidepressants, antipsychotics, and mood stabilizers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MMC powder capsuleEach capsule contains MMC powder for 500 mg | Other | MMC powder capsule |
| Calamansi powder capsuleEach capsule contains calamansi powder for 500 mg | Dietary supplement | Calamansi powder capsule |
Primary outcome
Concentrations of blood glucose
Time frame: At 0 minute before consumption, at 30, 60, 90, 120 minutes after consumption, and at days 91 after consumption
Concentrations of blood glucose were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in mg/dL unit
Concentrations of blood insulin
Time frame: At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption
Concentrations of blood insulin were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uU/mL (microunit/milliliter) unit
Concentrations of blood malondialdehyde
Time frame: At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption
Concentrations of blood malondialdehyde were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uM (micromolar) unit
1 secondary outcome
Levels of heart rate variability
Time frame: At 0-10 minutes before consumption, at 110-120 minutes after consumption, and at days 91 after consumption for 10 minutes
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2026.
- Individual participant dataSharing planned: No. There is no plan to make individual participant data available to other researchers.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Piyapong Prasertsri, Ph.D. principal investigator
Faculty of Allied Health Sciences, Burapha University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MMC powder capsule and Calamansi powder capsule in people with Calamansi Powder Capsule Supplementation, run by Burapha University at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Piyapong Prasertsri, Ph.D. (6638103166, piyapong@buu.ac.th), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentrations of blood glucose (time frame: At 0 minute before consumption, at 30, 60, 90, 120 minutes after consumption, and at days 91 after consumption). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.